Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$21.36
-1.0%
$19.74
$13.40
$25.23
$3.57B0.641.96 million shs2.60 million shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$16.09
+1.8%
$15.16
$9.57
$30.41
$2.22B0.961.54 million shs1.28 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$172.00
-0.3%
$166.65
$111.09
$183.00
$10.51B0.37498,807 shs802,076 shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$109.44
+3.1%
$108.75
$95.49
$148.06
$6.62B0.33825,571 shs754,237 shs
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$35.17
+0.6%
$33.57
$16.01
$44.34
$3.91B0.96907,152 shs412,361 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-2.49%-4.05%-0.14%+32.17%+32.74%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-1.74%+1.87%-1.62%+29.51%-39.21%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.22%-1.81%+5.64%+13.98%+26.56%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-0.73%-0.60%-1.99%-15.10%-0.57%
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
+0.66%-2.89%+15.45%-6.22%+101.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
4.6906 of 5 stars
4.43.00.00.03.14.22.5
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
3.9015 of 5 stars
3.42.00.03.42.92.50.0
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.519 of 5 stars
4.53.00.00.02.31.70.6
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.9088 of 5 stars
4.51.00.04.02.83.32.5
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
3.3789 of 5 stars
3.45.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.71
Moderate Buy$27.8830.50% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.75
Moderate Buy$43.71171.69% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$220.6728.29% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.92
Moderate Buy$184.0068.13% Upside
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
2.80
Moderate Buy$54.2854.32% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, ASND, ARWR, ACAD, and JAZZ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$73.00 ➝ $75.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform$19.00 ➝ $22.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$37.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
6/26/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00
6/23/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $38.00
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00
6/11/2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/6/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $30.00
6/5/2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$957.80M3.73$0.68 per share31.38$4.40 per share4.85
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$3.55M625.92N/AN/A$1.54 per share10.45
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M26.72N/AN/A($1.88) per share-91.49
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.07B1.63$31.09 per share3.52$67.72 per share1.62
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
$398.99M9.79N/AN/A$7.68 per share4.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$226.45M$1.3715.5928.114.7722.97%17.46%10.75%8/5/2025 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$599.49M-$1.40N/AN/A18.91N/A-45.33%-12.49%8/6/2025 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A716.67N/A-93.22%N/A-33.29%9/2/2025 (Estimated)
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$560.12M$7.5014.595.854.6111.86%26.62%9.14%7/30/2025 (Estimated)
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/5/2025 (Estimated)

Latest ZLAB, ASND, ARWR, ACAD, and JAZZ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q2 2025
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million
5/8/2025Q1 2025
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 million
5/7/2025Q1 2025
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.10$0.11+$0.01$0.11$239.32 million$244.32 million
5/6/2025Q1 2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
2.88
2.80
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.31
5.15
5.15
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.71
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
1.28
3.38
2.97
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
N/A
3.26
3.09
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510167.36 million120.00 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400138.10 million132.16 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
64061.13 million36.68 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,80060.51 million57.91 millionOptionable
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
1,869111.08 million105.57 millionOptionable

Recent News About These Companies

Amgen, Zai Lab succeed in gastric cancer study
Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?
Zai Lab (ZLAB) chief legal officer sells $212k in shares
Zai Lab (NASDAQ:ZLAB) Stock Rating Lowered by Wall Street Zen
Zai Lab Limited (ZLAB) - Yahoo Finance
Cantor Fitzgerald Expects Reduced Earnings for Zai Lab

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.36 -0.21 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$21.36 0.00 (-0.02%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.09 +0.29 (+1.84%)
Closing price 04:00 PM Eastern
Extended Trading
$16.10 +0.00 (+0.03%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$172.00 -0.60 (-0.35%)
Closing price 04:00 PM Eastern
Extended Trading
$172.28 +0.28 (+0.16%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$109.44 +3.32 (+3.13%)
Closing price 04:00 PM Eastern
Extended Trading
$104.63 -4.81 (-4.39%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$35.17 +0.20 (+0.57%)
Closing price 04:00 PM Eastern
Extended Trading
$35.22 +0.05 (+0.16%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.